Announced
Completed
Bristol-Myers Squibb completed the acquisition of Celgene for $90bn.
Financials
Sources
Press release
Bristol-Myers Squibb -
Investor Presentation
Bristol-Myers Squibb -
Transaction Fact Sheet
Bristol-Myers Squibb -
Letter to shareholders
Bristol-Myers Squibb -
Press release
Bristol-Myers Squibb -
Investor Presentation
Bristol-Myers Squibb -
Press release
Bristol-Myers Squibb -
Press release
Celgene -
Investor Presentation
Bristol-Myers Squibb -
Press Release
Bristol-Myers Squibb -
Press release
Bristol-Myers Squibb -
Investor presentation
Bristol-Myers Squibb -
Agreement and plan of merger
Bristol-Myers Squibb -
SEC Filling
Bristol-Myers Squibb -
Agreement and plan of merger
Bristol-Myers Squibb -
SEC Filling
Bristol-Myers Squibb -
Investor presentation
Bristol-Myers Squibb -
SEC Filling
Bristol-Myers Squibb -
Press release
Bristol-Myers Squibb -
Press release
Bristol-Myers Squibb -
Completion Announcement
Bristol-Myers Squibb -
Tags
Acquisition
Single Bidder
United States
pharmaceuticals & biotechnology
pharmaceuticals
biotechnology
Biotechnology
Public
Friendly
Completed
Majority
Pharmaceuticals
Domestic
Synopsis
Bristol-Myers Squibb Company completed the acquisition of Celgene Corporation, a biotechnology company, for an equity value of approximately $74bn. Under the terms of the agreement, Celgene shareholders received 1.0 Bristol-Myers Squibb share and $50 in cash for each share of Celgene. Celgene shareholders also receive one tradeable Contingent Value Right for each share of Celgene, which entitles the holder to receive a payment for the achievement of future regulatory milestones. Bristol-Myers Squibb divested itself of Otezla, a psoriasis treatment owned by Celgene to win approval from regulators and help smooth the path for the companies merger. FTC conditionally approved the acquisition.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.